Cannabis Compounds Stop Ovarian Cancer Cells From Surviving in Lab Tests

A pair of well-known marijuana compounds work in tandem to target ovarian cancer cells

Plant-derived cannabinoids appear effective against ovarian cancer cells in laboratory experiments. Research from Thailand reveals that cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) triggered cancer cell death through several biological pathways while normal ovarian cells required much higher concentrations to show similar effects. The compounds worked by disrupting energy production, triggering programmed cell death, and blocking the molecular signals that tumors need to survive.

Published in Frontiers in Pharmacology, the study saw scientists at Khon Kaen University test these cannabis compounds on ovarian cancer cells representing both treatment-sensitive and drug-resistant forms of the disease. The results showed a remarkable selectivity: CBD and THC attacked cancer cells at concentrations that left normal ovarian cells largely viable, suggesting these plant-derived molecules may exploit biological differences between malignant and healthy tissue.

Ovarian cancer claims around 185,000 lives worldwide each year, earning its reputation as one of the deadliest gynecological malignancies. The disease often evades early detection because symptoms remain vague and non-specific until cancer reaches advanced stages. Standard treatments involving surgery and platinum-based chemotherapy like cisplatin face significant hurdles including drug resistance, severe side effects, and frequent tumor recurrence.

How CBD and THC Were Tested on Drug-Resistant Cancer Cells

Researchers used three cell lines for their experiments: SKOV3 cells (inherently resistant to platinum-based drugs), A2780 cells (sensitive to platinum drugs), and IOSE80 cells (non-cancerous ovarian cells serving as a control). After 48 hours of treatment, CBD inhibited cancer cell growth at low micromolar concentrations, while normal ovarian cells required concentrations roughly four to five times higher to show similar effects. THC showed comparable patterns, with cancer cells dying at doses where normal cells remained largely viable.

The strategy became even more potent when researchers combined CBD and THC at equal amounts. Using the Chou-Talalay method, scientists confirmed synergistic interactions at specific CBD:THC ratios, with the strongest cooperation seen at a 1:1 ratio in A2780 cells. This means their combined impact exceeded what either compound could achieve alone.

Cannabis Compounds Block Cancer Cell Growth and Metastasis

Tests measuring whether cancer cells can reproduce indefinitely showed that CBD and THC treatments dramatically reduced both the number and size of cancer cell colonies. Cancer cells treated with the combination at half the individual doses formed far fewer colonies than untreated cells, while normal cells maintained their reproductive ability.

Migration and invasion represent critical steps in cancer’s deadly spread throughout the body. Using specialized chambers that allow cells to move through membranes, researchers found that CBD and THC suppressed both the migratory and invasive capabilities of ovarian cancer cells. The combination treatment produced the strongest inhibition, suggesting these compounds interfere with cellular behaviors linked to metastasis in laboratory models.

Analysis showed the first mechanism: treated cancer cells were halted at specific stages of the cell cycle before they could copy their DNA and divide. Both cancer cell lines showed this arrest pattern, stopping the uncontrolled proliferation characteristic of malignant cells, while normal cells continued their regular cycles.

Programmed cell death provided the second mechanism. Specialized staining techniques showed that the CBD-THC combination induced about 25-28% of cancer cells to self-destruct, compared to minimal effects on normal cells. This process, called apoptosis, represents one of the body’s natural ways of eliminating damaged or dangerous cells.

How Cannabinoids Disrupt Cancer Cell Energy Production

Cannabinoid treatment, especially the combination, disrupted the electrical charge that mitochondria need to function properly. Mitochondria serve as the cell’s power plants, and their failure signals cellular distress. At the same time, levels of reactive oxygen species (highly unstable molecules that damage cellular components) increased sharply in treated cancer cells, with some assays showing up to tenfold increases. This indicates severe oxidative stress that overwhelms defenses and drives cells toward death.

At the molecular level, analysis pinpointed the cannabinoids’ primary target: a communication system called the PI3K/AKT/mTOR pathway. This system, frequently overactive in ovarian cancer, sends constant “survive and grow” signals to cells. CBD and THC combination treatment dramatically reduced the activity of this pathway, effectively shutting down the cancer cell’s survival signals.

Researchers observed something notable about tumor suppressor regulation. A protein called PTEN, which normally acts as a brake on cancer growth, showed increased levels with cannabinoid treatment. PTEN works by opposing the PI3K/AKT/mTOR pathway. At the same time, chemical modifications that keep PTEN inactive decreased. This pattern is consistent with partial restoration of tumor-suppressive PTEN signaling, though the study did not directly measure the protein’s enzymatic activity.

Why Cannabis May Target Cancer Cells Differently

The authors suggest that differences in metabolism, signaling dependence, and stress tolerance between cancerous and normal cells may help explain this selectivity, although these factors were not directly tested in this study. Cancer cells often have altered receptors for cannabinoids, different metabolic needs, and broken survival controls compared to normal cells. These differences could explain why CBD and THC affect malignant cells more severely while normal cells remain less sensitive.

In cell-culture experiments, CBD and THC affected ovarian cancer cells through several coordinated mechanisms while normal ovarian cells showed greater resistance. The compounds halted cell division, triggered programmed death, blocked migration and invasion, disrupted cellular energy, and deactivated survival signals. These findings point to a targeted biological effect that now requires validation in animal models to determine whether this selectivity holds in living organisms and to assess toxicity, metabolism, and dosing before any clinical relevance can be determined.